3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now

The article argues that Pfizer, Novo Nordisk, and PDD Holdings are trading at steep valuation discounts, with forward P/E ratios of about 9x, under 14x, and 8x respectively. Pfizer is highlighted for $62.6 billion in revenue and a 6.8% dividend yield, Novo Nordisk for early demand for its Wegovy pill and potential obesity-drug growth, and PDD for 12% sales growth to about $17.7 billion despite a 11% drop in net income. The piece is largely a bullish valuation screen rather than a catalyst-driven news event.

Analysis

This is less a “cheap stocks” note than a timing signal on where the market is most willing to extrapolate mean reversion before the evidence is there. In all three cases, the core debate is not whether the businesses are impaired, but whether the next 2-4 quarters can stop estimate cuts from compounding into valuation compression. The setup favors patient capital only if management can demonstrate that pipeline, pricing, or trade normalization will bend near-term earnings revisions upward rather than merely stabilize revenue.

The second-order winner is not the most obvious direct competitor, but the firms with stronger operating leverage to the same secular theme and fewer transition costs. In obesity/GLP-1, that means the better-capitalized incumbent with cleaner manufacturing scale and more durable share gains can take the premium multiple, while the lagging large-cap pharma name becomes a classic “value trap until data inflects.” In China-linked e-commerce, the real risk is that trade friction changes the merchandising mix and logistics economics faster than top-line growth reflects; if tariffs persist, margin pressure can quietly outpace revenue growth for several quarters.

The contrarian miss is that these are all “cheap for a reason” stories, but the reasons are not equally reversible. Pfizer’s catalyst path is mostly idiosyncratic and longer-dated; Novo’s is data and launch execution; PDD’s is policy, which can turn sharply but is least controllable. That makes the market’s current discount potentially too severe on NVO and too modest on PDD if trade policy worsens, while PFE likely needs an actual pipeline readout, not just lower expectations, to re-rate meaningfully.

For positioning, the best risk/reward is to own the one with the clearest near-term catalyst and optionality, and fade the one where uncertainty is policy-driven and margin-sensitive. Dividends help PFE absorb time, but they do not solve patent-cliff math; NVO has the strongest probability of multiple expansion if launch data remains strong; PDD is a tactical trade, not a foundational long, unless trade headlines start to de-risk sourcing economics.

Key Decisions for Investors

• Go long NVO on a 3-6 month horizon; target a re-rating if GLP-1 launch data confirms durable demand. Risk/reward is favorable because multiple expansion can happen before full earnings recovery is visible.
• Hold PFE only as a patient income position, not as an aggressive total-return long; pair against a higher-quality large-cap pharma/biopharma basket if you want to isolate balance-sheet and pipeline optionality.
• Treat PDD as a tactical trade: buy only on policy-driven selloffs and size smaller than NVO. If tariff headlines worsen, cut quickly because margin compression can show up before revenue impact.
• Consider a pair trade long NVO / short PFE for the next 2-4 quarters: NVO has the cleaner catalyst path and better re-rating potential, while PFE faces more persistent earnings skepticism.
• For event-driven accounts, buy medium-dated PDD puts or put spreads into any near-term rally if trade negotiations remain uncertain; the skew is attractive because the downside can accelerate on policy headlines.